Hypofractionation in Prostate Cancer: Radiobiological Basis and Clinical Appliance

Hypofractionation in Prostate Cancer: Radiobiological Basis and Clinical Appliance

External beam radiation therapy with conventional fractionation to a total dose of 76-80 Gy represents the most adopted treatment modality for prostate cancer. Dose escalation in this setting has been demonstrated to improve biochemical control with acceptable toxicity using contemporary radiotherapy techniques. Hypofractionated radiotherapy and stereotactic body radiation therapy have gained a...

Moderate hypofractionation for prostate cancer

At the end of the last century, Brenner and Hall [1] argued that the fractionation sensitivity of prostate cancer was different from most tumors and normal tissues, with the opportunity to increase the therapeutic ratio by treating this cancer with hypofractionation (fewer, larger daily fractions). Nearly two decades later, the use of moderate hypofractionation for prostate cancer has become an...

Hypofractionation trials and radiobiology of prostate cancer

Dosimetric and Radiobiological Evaluation of Multiparametric MRI-guided Dose Painting in radiotherapy of Prostate Cancer

Introduction: Radiotherapy is one of the treatment options for locally advanced prostate cancer, however with standard radiation doses it is not always very effective. One of the strategies to improve the efficiency of radiotherapy is increasing the dose. In this study to increase tumor local control rates a new radiotherapy method, known as dose painting (DP) was investigated....

Prostate cancer and hypofractionation: reflections on recent randomised phase III clinical trial results

Four large randomised controlled trials testing modest hypofractionation for localised prostate cancer have reported efficacy and side effect outcomes within the last year (1-8). The studies were designed using different strategies which need to be considered when interpreting their results. The two largest trials, CHHiP (3,216 patients) (1-3) and PROFIT (1,206 patients) (4), have much in commo...